David Zaccardelli Sells 4,800 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

Verona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 4,800 shares of the company's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $4.38, for a total value of $21,024.00. Following the completion of the transaction, the chief executive officer now directly owns 14,591,736 shares in the company, valued at $63,911,803.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

David Zaccardelli also recently made the following trade(s):

• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Stock Down 1.7 %

NASDAQ VRNA traded down $0.57 during midday trading on Friday, hitting $33.86. 775,757 shares of the company traded hands, compared to its average volume of 913,695. Verona Pharma plc has a 52 week low of $11.39 and a 52 week high of $35.62. The company's 50-day simple moving average is $29.96 and its 200-day simple moving average is $21.47. The company has a market cap of $2.71 billion, a PE ratio of -43.97 and a beta of 0.44. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.53). During the same quarter in the prior year, the company earned ($0.11) earnings per share. As a group, equities research analysts forecast that Verona Pharma plc will post -2.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Maverick Capital Ltd. lifted its position in Verona Pharma by 74.2% during the second quarter. Maverick Capital Ltd. now owns 3,092,807 shares of the company's stock valued at $44,722,000 after acquiring an additional 1,316,998 shares during the last quarter. Candriam S.C.A. purchased a new stake in shares of Verona Pharma during the 2nd quarter valued at $11,177,000. NEA Management Company LLC lifted its holdings in shares of Verona Pharma by 9.3% during the 2nd quarter. NEA Management Company LLC now owns 5,584,753 shares of the company's stock valued at $80,756,000 after purchasing an additional 476,190 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Verona Pharma by 56.6% in the 2nd quarter. American Century Companies Inc. now owns 878,043 shares of the company's stock worth $12,697,000 after purchasing an additional 317,184 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. grew its stake in Verona Pharma by 10.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,314,349 shares of the company's stock worth $47,925,000 after buying an additional 300,000 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on VRNA shares. Truist Financial lifted their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the company a "buy" rating in a research note on Wednesday, October 9th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 target price on shares of Verona Pharma in a research report on Tuesday, October 1st. Canaccord Genuity Group increased their price target on Verona Pharma from $35.00 to $37.00 and gave the stock a "buy" rating in a research report on Monday, July 22nd. Finally, Wells Fargo & Company started coverage on Verona Pharma in a report on Thursday, October 3rd. They issued an "overweight" rating and a $50.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Verona Pharma presently has an average rating of "Buy" and an average target price of $39.33.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.